PA5-22096

antibody from Invitrogen Antibodies

Targeting: PIGR

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-22096

Provider

Invitrogen Antibodies

Product name

PIGR Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant protein fragment

Description

Recommended positive controls: Human milk. Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

0.39 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Loss of synergistic transcriptional feedback loops drives diverse B-cell cancers.

Andrews JM, Pyfrom SC, Schmidt JA, Koues OI, Kowalewski RA, Grams NR, Sun JJ, Berman LR, Duncavage EJ, Lee YS, Cashen AF, Oltz EM, Payton JE
EBioMedicine 2021 Sep;71:103559

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of PIGR in methanol-fixed HepG2 cells using a PIGR polyclonal antibody (Product # PA5-22096) at a 1:200 dilution.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

PIGR Polyclonal Antibody detects PIGR protein by immunofluorescent analysis. Sample: HepG2 cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: PIGR stained by PIGR Polyclonal Antibody (Product # PA5-22096) diluted at 1:500. Blue: Fluoroshield with DAPI . Scale bar= 10 µm.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 3 A novel super-enhancer associated with dysregulated high expression of PIGR and FCMR mRNA and protein. A) Genome browser screenshot shows signal for histone modifications (ChIPseq) and chromatin accessibility (FAIREseq - WUSM samples; DNase-seq - small intestine sample from Roadmap Epigenomic Project) for the FCMR / PIGR locus. Regulatory elements that were tested in luciferase assays are highlighted in gray. GeneHancer regulatory elements (red - promoter; gray - enhancer; darker color indicates higher confidence) and the identified super-enhancer are also shown. All tracks are RPKM normalized. Regions of copy number alteration (CNA) are shown by a red bar (amplifications identified in FL samples). B) Luciferase reporter assay results for all regulatory elements shown in ( A ). Assays were read in triplicate and performed at least twice. Mean with standard deviation shown. C-F) Expression of FCMR ( C-D ) and PIGR ( E-F ) determined by RNAseq ( C&E ) and RNA microarray ( D&F ) for BCL subtypes and healthy control B cells and B cell subsets (germinal center (GC) centroblasts (CB), centrocytes (CC), naive and memory B cells). RNAseq analyzed by DESeq2; microarrays analyzed by limma. * adj p > 0.05, ** adj p < 0.01, *** adj p < 0.001, **** adj p < 0.0001, ns not significant. G) Immunofluorescence microscopy for PIGR in purified primary CLL B-cells, MEC1 (CLL cell line), LS180 (colorectal cancer cell line), and HH (T-cell lymphoma cell line). Fig 3